Search the Newsreel

Form 4 Quest Diagnostics orporated For: 28 July By Investing.com

This article from Investing.com is a standard Form 4 filing for Quest Diagnostics (DGX) on July 28. It provides a brief mention of the filing and some stock market data. The article appears to be a stub for regulatory filings, providing minimal content beyond …

Quest Diagnostics Inc (DGX) Valuation: PE, PB & Fair Value Analysis

Quest Diagnostics Inc (DGX) currently holds a valuation score of 9.04, placing it 24th out of 75 in the Healthcare Providers & Services industry. Its P/E ratio stands at 25.17, which is at its recent high and significantly above its recent low. However, relevant …

Quest Diagnostics (NYSE: DGX) SVP acquires 34.0000 shares via dividend reinvestment

Mark E. Delaney, SVP & Chief Commercial Officer of Quest Diagnostics Inc. (NYSE: DGX), acquired 34.0000 shares of common stock at $206.807 per share through a dividend reinvestment plan. This transaction, reported early on Form 4, increased his direct holdings to 11,935.0000 shares, though …

Rothschild & Co Redburn Adjusts Quest Diagnostics Price Target to $251 From $233, Maintains Buy Rating

Rothschild & Co Redburn has increased its price target for Quest Diagnostics (NYSE: DGX) to $251, up from $233, while maintaining a Buy rating on the stock. This adjustment suggests a positive outlook from the firm regarding Quest Diagnostics' future performance.

Profusa (PFSA) pursues diagnostics acquisition and plans $7M convertible financing

Profusa (PFSA) has signed a non-binding term sheet to acquire a commercial-stage health diagnostics and toxicology testing company, whose 2025 net revenues are estimated at $111 million. Concurrently, Profusa plans to raise approximately $7 million through a subordinated convertible note. The company also announced …

Why Quest Diagnostics Stock Climbed This Past Week

Key Points Partnerships with other healthcare leaders are accelerating Quest's growth. AI is making the health insights provider more profitable.10 stocks we like better than Quest Diagnostics › Shares of Quest Diagnostics (NYSE: DGX) rose more than 8% last week after the medical testing …

Quest Diagnostics (DGX) Leads S&P 500 Healthcare Gainers with 8.15% Increase

Quest Diagnostics (DGX) was the top gainer in the S&P 500 Health Care Index Sector on July 26, 2026, with an 8.15% increase, despite a mixed market. The company, a leading diagnostic testing provider, has a P/E ratio of 24.19x and a GF Score …

Why Quest Diagnostics (DGX) Is Up 8.2% After Raising 2026 Guidance And Boosting Buybacks

Quest Diagnostics (DGX) Stock Gets Fair Value Boost After Q2 Beat And Higher Guidance

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Quest Diagnostics is back in focus after analysts lifted Fair Value estimates from US$223.44 to US$239.38, a move that has coincided with price …

Quest Diagnostics Incorporated Revenue Breakdown – NYSE:DGX

This article provides a revenue breakdown for Quest Diagnostics Incorporated (NYSE:DGX). Last year, the company generated $11.04 billion USD in revenue, with the Diagnostic Information Services segment contributing the majority at $10.79 billion USD. The United States was the primary geographical contributor, accounting for …

Quest Diagnostics Incorporated Stock 12‑Month Price Target Raised to $241.73, Implies 6% Upside

Quest Diagnostics Incorporated's average price target has been increased from $239.47 to $241.73 by 15 analysts, suggesting a 6% potential upside from its July 23 closing price. The consensus rating remains "Buy" with 10 Buys and 11 Holds among 21 covering analysts.

Quest Diagnostics Inc (DGX) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Quest Diagnostics Inc (DGX), highlighting its current earnings forecast score of 7.50, ranking 41st in its industry. Analysts have an average price target of $198.00 for DGX, with most recommending a "Buy" trend. The article also details …

QUEST DIAGNOSTICS INC : TRUIST SECURITIES RAISES TARGET PRICE TO $250 FROM $225

TRUIST SECURITIES has increased its target price for QUEST DIAGNOSTICS INC (DGX.N) to $250, up from the previous $225. This adjustment reflects an updated outlook on the company's financial prospects. The article, sourced from Reuters, reports on this change in analyst rating.

Quest Diagnostics Incorporated (DGX) Soars to 52-Week High, Time to Cash Out?

A strong stock as of late has been Quest Diagnostics (DGX). Shares have been marching higher, with the stock up 10.5% over the past month. The stock hit a new 52-week high of $237.78 in the previous session. Quest Diagnostics has gained 31.3% since …

Is Quest Diagnostics (DGX) Stock Still Worth More Than Its Price?

Quest Diagnostics projects $11.95B-$12.05B 2026 revenue while raising EPS outlook again

Earnings Call Insights: Quest Diagnostics (DGX) Q2 2026 MANAGEMENT VIEW * "Our strong performance in the second quarter demonstrates focused execution of our strategy to connect people and providers to innovative testing and actionable insights... In the quarter, we grew revenues by over 10%... …

Quest Diagnostics Stock Gains As Oncology Moves Impress Wall Street

Quest Diagnostics (DGX) shares rose by 7.52% following strong earnings and increased full-year guidance, driven significantly by advancements in its oncology division. The New York State Department of Health's clearance of Quest's Haystack MRD ctDNA liquid biopsy test for minimal residual disease detection, enabling …

Lockheed Martin, Quest Diagnostics, Thermo Fisher Scientific And Other Big Stocks Moving Higher On Thursd

Several large-cap stocks, including Lockheed Martin, Quest Diagnostics, and Thermo Fisher Scientific, are experiencing significant gains on Thursday after reporting better-than-expected quarterly financial results and, in many cases, raising their full-year guidance. Lockheed Martin reported strong earnings and sales, leading to an 11.4% jump …

Quest Diagnostics Surges After Hims- And Oura-Tied Beat

Quest Diagnostics put up a definitive beat Thursday, driven by solid demand across its consumer division, leading the stock to surge. Continue Reading

Quest Diagnostics stock hits all-time high at 227.31 USD By Investing.com

Quest Diagnostics (DGX) stock achieved an all-time high of $227.31, with shares currently trading at $232, reflecting a 22.07% increase over the past year. The company has consistently raised its dividend for 14 consecutive years and recently surpassed analyst expectations for its second-quarter results …

DGX Stock Up on Q2 Earnings & Revenue Beat, '26 View Raised

Quest Diagnostics (DGX) reported a notable beat on both Q2 2026 earnings and revenue, with adjusted earnings per share up 19.1% year over year and revenues rising 10.2%. This strong performance, driven by increased testing demand, led the company to raise its full-year 2026 …

Quest Diagnostics Releases Q2 2026 Financial Results

Quest Diagnostics Incorporated exceeded Wall Street expectations for its second-quarter 2026 results, reporting adjusted earnings of $3.12 per share against an estimated $2.85, and revenue of $3.04 billion, a 10.2% increase from Q2 2025. The company benefited from strong demand for laboratory services and …

Quest Diagnostics raises full-year guidance after Q2 revenue rises 10.2%

Quest Diagnostics reported strong Q2 2026 financial results, with net revenue increasing by 10.2% to $3.043 billion and adjusted diluted EPS rising 19.1% to $3.12, both surpassing analyst estimates. Attributing the growth to execution across various channels and sustained demand, the company raised its …

Earnings Flash (DGX) Quest Diagnostics Incorporated Reports Q2 Revenue $3.04B, vs. FactSet Est of $2.97B

Quest Diagnostics Incorporated (DGX) reported Q2 revenue of $3.04 billion, surpassing FactSet's estimate of $2.97 billion. This financial news indicates a stronger-than-expected performance for the diagnostic testing and information services provider in the second quarter of 2026. Earlier, the company also announced Q2 adjusted …

Earnings Flash (DGX) Quest Diagnostics Incorporated Posts Q2 Adjusted EPS $3.12 per Share, vs. FactSet Est of $2.82

Quest Diagnostics Incorporated (DGX) reported Q2 adjusted EPS of $3.12 per share, exceeding the FactSet estimate of $2.82. The company also announced Q2 revenue of $3.04 billion, surpassing FactSet's estimate of $2.97 billion, and expects full-year 2026 revenue between $11.95 billion and $12.05 billion.

Quest Diagnostics stock rises 5% on strong Q2 beat, raised guidance

Quest Diagnostics (NYSE:DGX) reported strong second-quarter results, surpassing analyst expectations for both EPS and revenue. The company also raised its full-year 2026 guidance for both revenue and adjusted EPS, leading to a nearly 5% rise in pre-market trading. This performance was attributed to robust …

Quest Diagnostics climbs as Q2 earnings top estimates, guidance raised (DGX:NYSE)

Quest Diagnostics (DGX) shares rose by approximately 11% after the company announced second-quarter earnings that exceeded Wall Street's expectations. The diagnostic testing company also raised its full-year 2026 guidance above consensus. Adjusted earnings per share for the quarter were reported at $3.12, surpassing estimates.

Quest Diagnostics Q2 Earnings Call Highlights

Quest Diagnostics Incorporated Q2 2026 Earnings Call Summary - Moby Strategic Performance Drivers Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here. Revenue …

QUEST DIAGNOSTICS ($DGX) Releases Q2 2026 Earnings

Quest Diagnostics Earnings: Strong Quarterly Results Spur Optimistic Outlook for Second Half

Quest’s (NYSE:DGX) Q2 CY2026: Beats On Revenue, Stock Soars

Quest's (NYSE:DGX) Q2 CY2026: Beats On Revenue, Stock Soars Healthcare diagnostics company Quest Diagnostics (NYSE:DGX) beat Wall Street's revenue expectations in Q2 CY2026, with sales up 10.2% year on year to $3.04 billion. Its non-GAAP profit of $3.12 per share was 10.5% above analysts' …

Quest Diagnostics earnings on deck as testing growth accelerates

Quest Diagnostics is set to report second-quarter earnings, with analysts expecting continued revenue and EPS growth. Investors will focus on the company's advanced diagnostics investments, routine testing demand, and use of AI to improve margins, as well as management's full-year outlook. The diagnostic testing …

Quest Diagnostics stock trades steadily as recent earnings and data volumes shape outlook

Quest Diagnostics (DGX) stock performance remains steady, supported by stable revenue growth and modest EPS expansion. The company reported $2.37 billion in revenue and $2.05 diluted EPS in a recent quarter, reflecting operational efficiency despite modest 1.7% revenue growth. With a market capitalization around …

Quest Diagnostics Rallies Ahead of Earnings as Investors Weigh Growth Initiatives | DGX Stock News

Quest Diagnostics stock trades steadily as investors weigh recent revenue growth and dividend income

Quest Diagnostics stock reflects steady fundamentals, with investors focusing on recent revenue trends, earnings resilience, and cash returns via dividends alongside the broader US healthcare diagnostics sector. The company's financials show moderate revenue growth, stable earnings, and a consistent dividend payout, making it a …

DGX4807226 Bond Coupon Profile — Rate & Payments

This article provides the coupon profile for the DGX4807226 bond issued by Quest Diagnostics Incorporated. It details that the current coupon rate is 4.20% and the next payment is scheduled for December 31, 2026. The article highlights the bond's interest payment overview and offers …